What Changes When Sodium Chloride Is Partly Replaced
Potassium-containing lower-sodium table salt is a reformulation of a familiar ingredient, and the focus here is the chain between its composition and what the body experiences. To judge the intervention, read its sodium chloride and potassium chloride proportions as changes in exposure, then trace how those changes may affect biomarkers, blood pressure, taste and safety. The key lesson is that none of those steps is guaranteed by a product label alone.
Regular table salt is predominantly sodium chloride, or NaCl. A lower-sodium substitute usually replaces part of that NaCl with potassium chloride, or KCl; some products also contain magnesium, calcium, chitosan or other ingredients. The replacement is intended to preserve enough of salt's familiar flavor while delivering less sodium. But it also introduces more potassium, so the same reformulation that may improve one risk factor can create a concern for people who cannot safely clear potassium.
NaCl and KCl are two axes of the same intervention
A percentage on a packet answers only one question: how the mixture has been composed. It does not by itself answer how much a person will use, what the rest of their diet contains, or whether their health status makes the added potassium appropriate. The recent systematic review and network meta-analysis made this distinction explicit by classifying substitutes in three different ways.
The first approach grouped products by their primary ingredients. A K-salt contains a mixture of KCl and NaCl. Other groups add calcium, magnesium or chitosan as substantial components. This approach is useful when asking whether a non-sodium ingredient might have its own physiological or sensory role. It does not tell us that products with similar names have identical proportions or evidence.
The second approach grouped products by KCl content. The review called products containing 50–65% KCl high-potassium, those containing 25–40% moderate-potassium, and those containing 5–20% low-potassium. The third approach grouped them by the NaCl left in the mixture: 80–97% was reduced-sodium, 60–79% low-sodium, 40–59% very low-sodium and 2–39% extremely low-sodium.
These are overlapping descriptions, not rival identities. For example, a mixture of 75% NaCl and 25% KCl is a K-salt when classified by its main ingredients. It is also a moderate-potassium substitute when classified by KCl content, and a low-sodium substitute when classified by NaCl content. Calling it one of those things does not make the other two descriptions disappear. The correct interpretation depends on the question being asked.
That matters because “lower sodium” can sound like a complete account of the product. It is not. Two products can both be marketed as lower-sodium while differing in the amount of KCl, the presence of other minerals, the amount of sodium that remains, and the evidence available for their particular formulation. Conversely, a product can have more potassium without having demonstrated a larger or more reliable health effect.
The WHO evidence review reflects this mixture of formulations. It included substitutes of any type or duration if they aimed to replace some dietary sodium with another mineral or compound, but 23 of its 26 adult trials examined substitutes that replaced sodium with potassium. In those products, NaCl ranged from 41% to 75% and KCl from 19% to 50%. Those ranges show why the intervention should be treated as a class with internal variation rather than as a single standardized dose.
The composition also changes the comparison with regular salt. If the amount of substitute used is held constant, a mixture with less NaCl can supply less sodium than regular salt. If it contains KCl, it can supply more potassium at the same time. But the amount of sodium a person actually consumes depends on whether they use the substitute instead of regular salt, whether they use more because the flavor seems weaker, and how much sodium arrives from other foods. Composition sets the potential exposure; behavior and the surrounding diet determine the realized exposure.
The product's purpose is therefore not to add potassium indiscriminately. WHO recommends naturally potassium-rich foods, such as beans, peas, nuts and green vegetables, as the primary sources of dietary potassium when people are seeking to increase it. A potassium-containing salt substitute is a sodium-reduction intervention with a particular trade-off, not a general-purpose potassium supplement.
A label also cannot settle whether the product is appropriate for a particular person. The later safety question is not simply whether a product contains less sodium. It is whether the added potassium can be handled safely in the context of kidney function, medicines, other medical conditions and the rest of the diet. That is why composition is the starting point for judgment, not its conclusion.
The sequence separates the intervention from its consequences. The mixture is the trigger for a change in sodium and potassium exposure. Urinary and serum electrolyte measurements are intermediate signals. Blood pressure is a more clinically meaningful outcome, but it is still an average response observed across studies. Taste, adherence and food setting can determine whether the intended mixture reaches the body at all, while health status and medicines can change the safety of the potassium exposure.
From a changed mixture to a changed outcome
The most direct pathway begins with sodium. Sodium chloride in the diet contributes to sodium exposure, and high sodium intake is associated with higher blood pressure. Replacing part of NaCl with KCl can lower the sodium delivered by a given amount of table salt. This is the intervention's first intended mechanism: change the input so that less sodium enters the diet.
Potassium creates a second pathway. The sources note that replacing NaCl with KCl may provide an advantage beyond sodium reduction because potassium can contribute to blood-pressure lowering. The newer review discusses mechanistic evidence suggesting that potassium enrichment may contribute substantially to the observed blood-pressure effect. Yet the same review did not find a significant difference in blood-pressure reduction between the different potassium and sodium concentration groups. The evidence supports a combined intervention, not a settled claim that potassium is the sole or dominant cause in every formulation.
A useful way to keep the causal chain clear is to distinguish a mediator from an outcome. A mediator is a change through which an intervention may operate. In this case, urinary sodium, urinary potassium and serum potassium can reveal that the body's electrolyte exposure changed. Blood pressure is an outcome that matters directly for cardiovascular risk. Cardiovascular events and mortality are still further outcomes, and require longer follow-up and more events than a short-term electrolyte measurement.
The WHO review found average biomarker changes consistent with the intended design. Across 11 randomized trials, 24-hour urinary sodium fell by about 19.98 mmol, or 459 mg, on average, while urinary potassium rose by about 11.44 mmol, or 450 mg. Serum potassium increased by a mean 0.12 mmol/L. These are group averages, not instructions for what any one person's laboratory result should be. The urinary findings were highly heterogeneous, with I² values of 91% for sodium and 82% for potassium, and WHO did not grade those outcomes.
Heterogeneity means that the studies did not produce one uniform size of change. The reasons may include differences in the substitute, how much participants used, baseline diet, duration, adherence and the other sources of sodium or potassium in their meals. The newer review also found that lower NaCl content did not map consistently onto lower urinary sodium, suggesting that incomplete replacement or additional dietary sodium could blur the relationship between the label and actual intake. A composition can create an opportunity for lower sodium without proving that total sodium has fallen by a predictable amount.
The next link is blood pressure. WHO's evidence review found that assigning adults to use lower-sodium salt substitutes rather than regular salt reduced systolic blood pressure by an average of 4.76 mmHg and diastolic blood pressure by 2.43 mmHg over follow-up ranging from 56 days to five years. The newer network analysis likewise found reductions in blood pressure across several substitute categories. These results make the intervention biologically and clinically plausible, but they do not mean that every product produces the same reduction or that every user responds in the same way.
The difference between an exposure, a mediator and an outcome prevents two common errors. The first is to say that a product “lowers blood pressure” merely because its sodium content is lower. The trials provide evidence for an average blood-pressure effect, but that effect was measured in particular populations using particular products. The second is to treat a change in serum or urinary potassium as either proof of benefit or proof of harm. It confirms that the potassium side of the intervention is real; it does not by itself determine the net clinical result.
Taste and adherence form another link in the chain. Potassium chloride can alter flavor, and the practical intervention works only if people use the substitute instead of regular salt and continue using it. The network review found no evidence that substitutes were less acceptable overall than regular salt in the studied trials. It also notes that taste perception and adherence can vary by formulation and culture. WHO identified bad taste, lack of awareness, limited availability, higher price and lack of perceived benefit as barriers to uptake. A product that is not accepted cannot deliver its intended composition consistently.
Food setting changes the pathway too. Most of the randomized evidence concerns discretionary salt: what people add while cooking or eating. If a person's largest sodium sources are manufactured food, restaurant meals or condiments such as soy sauce and fish sauce, replacing the salt in the home kitchen may leave much of the total exposure unchanged. The substitute may still be useful for the part of the diet it reaches, but its effect cannot be inferred from the amount of sodium printed on the substitute alone.
Finally, safety can interrupt the pathway. Increasing potassium exposure is not equivalent to increasing a neutral flavoring ingredient. WHO excludes people with kidney impairments and other conditions that compromise potassium excretion from its recommendation. The newer review also calls for caution in chronic or undiagnosed kidney disease, with potassium-sparing medications and in diabetes. The same average potassium increase that is tolerated by a selected trial population may not be safe for someone whose body cannot regulate potassium in the same way. This is a boundary condition on the intervention, not evidence that every person who uses a substitute will develop a problem.
The intuitive conclusion that “more potassium must mean more benefit” fails because the pathway has several independent limits. Higher KCl may change urinary potassium more, but the network analysis did not establish a clear superiority in blood-pressure reduction between substitute categories. The evidence for mortality and cardiovascular events is also less certain for some high- or very-low-sodium groups than for moderate-potassium and low-sodium groups. More of one component can change both the potential benefit and the potential harm without resolving either one.
Reading the mixture correctly therefore requires four separate questions. What sodium and potassium exposures does it create? What happens to intermediate measures such as urinary or serum electrolytes? What outcomes have actually been observed, and with what certainty? And can the intended person use it safely and consistently in the food setting where the sodium reduction is supposed to occur? A product label can begin the inquiry, but it cannot answer all four questions.
The most important result of this mechanism is a disciplined expectation. Partial replacement can make lower sodium possible and can produce a meaningful average blood-pressure reduction. It can also raise potassium exposure, interact with health status and medicines, and fail to reach the main sources of sodium. The next step is to examine the trials as evidence: who was enrolled, what was compared, which outcomes were measured, and how strongly each conclusion is supported.